Fan Yu-Yan, Nishiyama Akira, Fujisawa Yoshihide, Kobori Hiroyuki, Nakano Daisuke, Matsuura Junji, Hase Naoki, Hitomi Hirofumi, Kiyomoto Hideyasu, Urata Hidenori, Kohno Masakazu
Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University Medical School, Japan.
J Pharmacol Sci. 2009 Sep;111(1):82-90. doi: 10.1254/jphs.09152fp. Epub 2009 Aug 29.
Recent studies indicate a role of chymase in the regulation of angiotensin II (AngII) formation in cardiovascular and renal tissues. We investigated a possible contribution of chymase to AngII formation and to renal fibrosis in unilateral ureteral obstruction (UUO). Eight-week-old Syrian hamsters were subjected to UUO and treated with vehicle, the specific chymase inhibitor (CI) 4-[1-(4-methyl-benzo[b]thiophen-3-ylmethyl)-1H-benzimidazol-2-ylsulfanyl]-butyric acid (50 mg/kg, twice a day, p.o.), or the selective AT(1)-receptor blocker olmesartan (10 mg/kg per day, p.o.) for 14 days. UUO-induced renal interstitial fibrosis was associated with increases in renal mRNA levels of alpha-smooth muscle actin (SMA), type I collagen, and transforming growth factor (TGF)-beta. The UUO hamsters showed markedly higher AngII contents and increased AT(1)-receptor mRNA level in the obstructed kidney than sham-operated ones. In contrast, angiotensin-converting enzyme (ACE) protein expression was significantly lower in UUO hamsters. In UUO hamsters, treatment with CI or olmesartan significantly decreased AngII levels in renal tissue and mRNA levels of alpha-SMA, type I collagen, and TGF-beta and ameliorated tubulointerstitial injury. On the other hand, neither CI nor olmesartan changed systolic blood pressure, renal ACE, and AT(1)-receptor protein levels. These data suggest that chymase-dependent intrarenal AngII formation contributes to the pathogenesis of interstitial fibrosis in obstructed kidneys of hamsters.
近期研究表明,糜酶在心血管和肾脏组织中血管紧张素II(AngII)形成的调节过程中发挥作用。我们研究了糜酶在单侧输尿管梗阻(UUO)中对AngII形成及肾纤维化的可能作用。将8周龄的叙利亚仓鼠进行UUO手术,并分别给予溶媒、特异性糜酶抑制剂(CI)4-[1-(4-甲基-苯并[b]噻吩-3-基甲基)-1H-苯并咪唑-2-基硫烷基]-丁酸(50 mg/kg,每日两次,口服)或选择性AT(1)受体阻滞剂奥美沙坦(10 mg/kg每日,口服),持续14天。UUO诱导的肾间质纤维化与肾α-平滑肌肌动蛋白(SMA)、I型胶原和转化生长因子(TGF)-β的mRNA水平升高相关。与假手术组相比,UUO仓鼠梗阻肾脏中的AngII含量显著更高,且AT(1)受体mRNA水平升高。相反,UUO仓鼠中血管紧张素转换酶(ACE)蛋白表达显著降低。在UUO仓鼠中,CI或奥美沙坦治疗可显著降低肾组织中的AngII水平以及α-SMA、I型胶原和TGF-β的mRNA水平,并改善肾小管间质损伤。另一方面,CI和奥美沙坦均未改变收缩压、肾ACE和AT(1)受体蛋白水平。这些数据表明,糜酶依赖性肾内AngII形成参与了仓鼠梗阻肾脏间质纤维化的发病机制。